Supplemental tables/figures

Similar documents
QStatin Update Information

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database

Validation of QRISK2 (2014) in patients with diabetes

RESEARCH. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

QDScore 2011 Annual Update Information

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

RESEARCH. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study

Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care

Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study

Epidemiologic Measure of Association

Cardiovascular risk factor appraisal art or science?

ORIGINAL ARTICLE. Epidemiology

Europe PMC Funders Group Author Manuscript Heart. Author manuscript; available in PMC 2016 May 17.

Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care

Kjersti Stormark Rabanal, 1 Haakon Eduard Meyer, 1,2 Romana Pylypchuk, 3 Suneela Mehta, 3 Randi Marie Selmer, 1 Rodney T Jackson 3.

CVD risk calculation

Identification of subjects at high risk for cardiovascular disease

Cardiovascular Risk Assessment and Management Making a Difference

AN INDEPENDENT VALIDATION OF QRISK ON THE THIN DATABASE

University of Dundee

Antihypertensive Trial Design ALLHAT

COMPETING INTEREST OF FINANCIAL VALUE

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. Produced by: National Cardiovascular Intelligence Network (NCVIN)

Supplementary Online Content

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

RESEARCH. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

Ethnic group differences in CVD risk estimates using JBS2 and QRISK2 risk scores. Dr Andrew R H Dalton

Access from the University of Nottingham repository:

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Antidepressant use and risk of adverse outcomes in people aged years: cohort study using a primary care database

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

Welcome to this third module in a three-part series focused on epidemiologic measures of association and impact.

Overweight and obesity: where are we and where are we heading?

RESEARCH. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Economically efficient approaches to address chronic disease in developing countries

Cardiovascular disease profile

RESEARCH. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study

Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Socioeconomic Factors, Work and Chronic Diseases

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012

BMJ Open. Cardiovascular medicine. General diabetes < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, PREVENTIVE MEDICINE, PRIMARY CARE

Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database

RESEARCH. Julia Hippisley-Cox, Carol Coupland. open access ABSTRACT

What s new in cardiovascular disease risk assessment and management for primary care clinicians

BMJ Open. General practice / Family practice. Keywords: PREVENTIVE MEDICINE, PRIMARY CARE, THERAPEUTICS

CONTRIBUTING FACTORS FOR STROKE:

Baldness and Coronary Heart Disease Rates in Men from the Framingham Study

Tuberculosis in England 2018 report (presenting data to end of 2017) Tables and figures slide set

CVD Prevention, Who to Consider

Statistical Fact Sheet Populations

Cardiovascular disease risk prediction equations in primary care patients in New Zealand: a derivation and validation study

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C

Framingham Heart Study Longitudinal Data Documentation

Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis

Update on Current Trends in Hypertension Management

Supplementary Online Content

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD)

Getting serious about preventing cardiovascular disease

Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

Randomized Design of ALLHAT BP Trial

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

Type of intervention Primary prevention; secondary prevention. Economic study type Cost-effectiveness analysis and cost utility analysis.

International IBD Genetics Consortium

The NHS Health Check in England: an evaluation of the first 4 years

JSNA Data Refresh 2013/14 Diabetes Barnet

Epidemiology and Prevention

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants

Hypertension Clinical case scenarios for primary care

BHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over

MPharmProgramme. Hypertension (HTN)

EuroPrevent 2010 Fatal versus total events in risk assessment models

CARDIOMETABOLIC SYNDROME

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

European Journal of Cardiovascular Prevention & Rehabilitation

Supplementary Online Content

Cardiovascular Diseases in CKD

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Inequalities in health due to ethnicity and social deprivation an analysis of primary care data from one inner city area over a three year period

Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Prediction of Coronary Heart Disease in a Population With High Prevalence of Diabetes and Albuminuria The Strong Heart Study

CVD Risk of Hypertension. Regina Giblin CVD Clinical Development Coordinator

Diabetes. Ref HSCW 024

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Transcription:

Supplemental tables/figures Table S:Baseline variables included in calculation of QRISK and Framingham scores Ethnicity (European, Indian Pakistani, Bangladeshi, Black African, Black Caribbean) QRISK Age, years Sex Smoking: Current or nonsmoker (includes ex-smoker) Systolic blood pressure Total cholesterol: high density lipoprotein ratio Type diabetes Body mass index Treated hypertension Townsend deprivation score (output area level census data) Family history of CHD in first degree relative under 6. Available only from survivors at year follow-up: history of CHD in parents diagnosed at <6years) Rheumatoid arthritis. Not available. Chronic renal disease. Not available. Atrial fibrillation. Available only in subset. Left ventricular hypertrophy. Available only in subset. Sensitivity analyses only. Otherwise null values assumed. Null values assumed Null values assumed Null values assumed. Framingham For South Asian men score is multiplied by. Sensitivity analyses only. (multiply score by. if any positive family history) Otherwise null values assumed. Sensitivity analyses only. Otherwise null values assumed.

Table S. Baseline characteristics of those lost to follow-up or excluded from analyses due to missing baseline data (means±sd, geometric means(9% CIs) Men European Indian Asian African Caribbean N 8 6 Age.±7..±7..±.9 SBP, mm Hg ±7 7±8 ±9 HDL cholesterol.(.7,.).(.,.8).(.7,.) Cholesterol: HDL ratio.9(.77,.).(.7,.).8(.6,.8) Body mass index 6.±.8.9±. 6.±. Smoking: Never Ex (%) 76(%) 6(66%) (8%) 67(7%) (%) Current 6(%) 6(%) 6(%) Diabetes (%) 99(9%) 9(%) Treated hypertension (%) (6%) 8(9%) Townsend score.(.,.8).(.8,.).(.9,.7) Women N Age.6±6..±7.8.9±.6 SBP, mm Hg ±7 9± ±6 HDL cholesterol.(.6,.6).(.,.6).6(.,.7) Cholesterol: HDL ratio.86(.6,.).(.8,.9).(.8,.6) Body mass index 6.±. 6.±. 9.6±.9 Smoking: Never Ex (8%) (%) 6(96%) 8(8%) (%) Current (%) (%) 6(6%) Diabetes 7(6%) 9(8%) 6(6%) Treated hypertension (%) 8(6%) (%) Townsend score.(.9,.9).6(.,.).(.7,.8)

Supplemental Table S: Comparison of QRISK and Framingham scores in classification into low and high year of cardiovascular events and observed and predicted QRISK Total MEN Framingham score (with South Low (<%) High (>=%) Asian ethnicity adjustment): low (<=%) Number of men 77 6 (.%) 87 Number of events ( year 9(8.(7., 9.8)) 7(.(7.6, 9.6)) 6(8.7(7.,.)) (9%) QRISK: geometric means(9% 7.(6.9, 7.).(.7,.9) 7.(7., 7.) 9.(9., 9.) 6.7(.9, 7.) 9.(9., 9.7) means(9% Framingham (with South Asian ethnicity adjustment): high (>%) Number of men (8.%) 7 9 Number of events( year 8(6.6(., 7(.(7., (.(.8, 8.)) (9%).9)).)) QRISK: geometric means(9%.(.8,.6) 9.(8.7,.).8(.,.).9(.,.).(.,.) 9.9(9.,.) means(9% WOMEN Framingham score: low (<=%) Number of women 87 (.7%) 8 Number of events( year 8(6.9(., 8.8)) 8(6.9(., 8.8)) (9%) QRISK: geometric means(9%.(.,.6).8(.,.).(.,.8).(.8,.).(., 8.).(.9,.) means(9% Framingham): high (>%) Number of women 9 (6.%) 8 Number of events( year 7(.(.,.) (6.(6., (.6(7.,.6)) (9%)%).) QRISK: geometric means(9% 6.(., 7.) 8.(6.,.).(.6,.87) means(9%.(.6,.) 8.7(6.9,.6) 6.(., 7.7)

Figure S: Follow-up of SABRE cohort: Those without CVD at baseline Baseline 988-9 Europeans Indian Asians African Caribbeans N=6 CVD N=7 CVD N=8 at baseline at baseline N=6 N=8 CVD at baseline N=9 Traced at follow-up 8- N=8 (.6% embarked,.6% no address) N=9 N=9 (.% embarked, % no address) N= N=76 (.7% embarked,.6% no address) N=6 Follow-up data available to years after baseline N=866(9% of traced) N=77 (9% of traced) N=78 (9% of traced) Follow-up data available to years + complete baseline factor data N=8 (88% of traced, 8% of total) N=7 (86% of traced, 8% of total) N= (86% of traced, 7% of total)

Ratio of predicted to observed Ratio of predicted to observed Ratio of predicted to observed Figure S) : Plots of year predicted vs observed ratios (9% CIs), by tenths of predicted, for QRISK and Framingham (with South Asian male ethnicity adjustment) scores a)men i)qrisk Europeans ii)framingham 6 7 8 9 6 7 8 9 South Asians 6 7 8 9 6 7 8 9 African Caribbeans 6 7 8 9 Deciles of predicted 6 7 8 9 Deciles of predicted

Ratio of predicted to observed Ratio of predicted to observed Ratio of predicted to observed Figure S(continued) b)women i)qrisk Europeans ii) Framingham 6 7 8 9 6 7 8 9 South Asians 6 7 8 9 6 7 8 9 African Caribbeans 6 7 8 9 Deciles of predicted 6 7 8 9 Deciles of predicted